CoChat

Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361

Open access
Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., Li, J., Maegley, K., Newell, D. R., Notarianni, E., Stratford, I. J., Skalitzky, D., Thomas, H. D., Wang, L.-Z., Webber, S. E., Williams, K. J., Curtin, N. J. · 2004 · JNCI Journal of the National Cancer Institute

The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Poly(ADP-ribose) polymerase-1 (PARP-1) facilitates the repair of DNA strand breaks. Inhibiting PARP-1 increases the cytotoxicity of DNA-damaging chemotherapy and radiation therapy in vitro. Because classical PARP-1 inhibitors have limited clinical utility, we investigated whether AG14361, a novel potent PARP-1 inhibitor (inhibition constant <5 nM), enhances the effects of chemotherapy and radiation therapy in human cancer cell cultures and xenografts. METHODS: The effect of AG14361 on the antitumor activity of the DNA alkylating agent temozolomide, topoisomerase I poisons topotecan or irinotecan, or x-irradiation or gamma-radiation was investigated in human cancer cell lines A549, LoVo, and SW620 by proliferation and survival assays and in xenografts in mice by tumor volume determination. The specificity of AG14361 for PARP-1 was investigated by microarray analysis and by antiproliferation and acute toxicity assays in PARP-1-/- and PARP-1+/+ cells and mice. After intraperitoneal administration, the concentration of AG14361 was determined in mouse plasma and tissues, and its effect on PARP-1 activity was determined in tumor homogenates. All statistical tests were two-sided. RESULTS: AG14361 at 0.4 micro M did not affect cancer cell gene expression or growth, but it did increase the antiproliferative activity of temozolomide (e.g., in LoVo cells by 5.5-fold, 95% confidence interval [CI] = 4.9-fold to 5.9-fold; P =.004) and topotecan (e.g., in LoVo cells by 1.6-fold, 95% CI = 1.3-fold to 1.9-fold; P =.002) and inhibited recovery from potentially lethal gamma-radiation damage in LoVo cells by 73% (95% CI = 48% to 98%). In vivo, nontoxic doses of AG14361 increased the delay of LoVo xenograft growth induced by irinotecan, x-irradiation, or temozolomide by two- to threefold. The combination of AG14361 and temozolomide caused complete regression of SW620 xenograft tumors. AG14361 was retained in xenografts in which PARP-1 activity was inhibited by more than 75% for at least 4 hours. CONCLUSION: AG14361 is, to our knowledge, the first high-potency PARP-1 inhibitor with the specificity and in vivo activity to enhance chemotherapy and radiation therapy of human cancer.

Overview

Integrity signals

Registry

Crossref · 10.1093/jnci/djh005

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 61 references

Research works printed but not linked: 5

  1. Ding, 1994, Cancer Research, 54, 4627
  2. 1996, Oncology reports, 3, 317
  3. el-Said, 1999, Radiation oncology investigations, 7, 163, 10.1002/(sici)1520-6823(1999)7:3<163::aid-roi5>3.0.co;2-m · doi:10.1002/(sici)1520-6823(1999)7:3<163::aid-roi5>3.0.co;2-m
  4. Williams, 2002, British Journal of Cancer, 86, 1157, 10.1038/sj.bjc.6600182 · doi:10.1038/sj.bjc.6600182 · Paper page
  5. Aquilina, 1998, Cancer Research, 58, 135

Cited by

See all 506

Metadata

Authors
Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., Li, J., Maegley, K., Newell, D. R., Notarianni, E., Stratford, I. J., Skalitzky, D., Thomas, H. D., Wang, L.-Z., Webber, S. E., Williams, K. J., & Curtin, N. J.
Affiliations
Newcastle University (GB)
Corresponding author
Calabrese, C. R.
Venue
JNCI Journal of the National Cancer Institute
Published
2004-01-06
Volume
96
Issue
1
Pages
56-67
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2100457669
Cited by
487
References
62
Citations by year
2026: 6 · 2025: 9 · 2024: 4 · 2023: 30 · 2022: 14 · 2021: 18 · 2020: 18 · 2019: 17 · 2018: 18 · 2017: 25 · 2016: 27 · 2015: 30 · 2014: 25 · 2013: 25 · 2012: 23
FWCI
10.91
Type
journal article
Language
en
Open access
Locations
  • JNCI Journal of the National Cancer Institute (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
Medical Research Council (G0500366)
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords
PARP-1 inhibitors, chemosensitization, radiosensitization, temozolomide, topotecan, irinotecan, DNA repair, DNA strand break repair, radiation damage, xenografts, drug toxicity, anticancer activity, colorectal cancer, lung cancer
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, Temozolomide, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzodiazepines, Carcinoma, Non-Small-Cell Lung, Dacarbazine, Enzyme Inhibitors, Gamma Rays, Humans, Lung Neoplasms, Poly(ADP-ribose) Polymerases, Radiation-Sensitizing Agents, Transplantation, Heterologous, Colorectal Neoplasms, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Cell Line, Tumor, Mice, Azulenes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361. https://app.cochat.ai/papers/10.1093/jnci/djh005
The paper
Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., Li, J., Maegley, K., Newell, D. R., Notarianni, E., Stratford, I. J., Skalitzky, D., Thomas, H. D., Wang, L.-Z., Webber, S. E., . . . Curtin, N. J. (2004). Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djh005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.